ABEO Research and Charts

ABEO - Abeona Therapeutics Inc (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2025-06-30)

Last 5.68	Change ⇓ -0.07 (-1.22%)	Volume 948,608
	Open 5.77	High 5.80	Low 5.64

8EMA (Daily) 5.87	40EMA (Daily) 5.95	50EMA (Daily) 5.90	STO (Daily) 15.090	MACD Hist (Daily) -0.133
8EMA (Weekly) 5.902	40EMA (Weekly) 5.67	50EMA (Weekly) 5.64	STO (Weekly) 62.360	MACD Hist (Weekly) 0.021


Company Profile
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its lead clinical programs consist of EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A, and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.